Join        Login             Stock Quote

Epizyme Files For IPO Of Up To $69M

 April 18, 2013 02:26 PM

(By Balachander) Epizyme Inc., a biopharmaceutical company developing therapeutics for the treatment of genetically defined cancers, has filed to raise up to $69 million in an initial public offering (IPO) of its common stock.

The filing with the U.S. federal regulators did not disclose how many shares the Cambridge, Massachusetts-based company plans to offer or the pricing terms.

Epizyme is conducting a Phase 1 clinical trial of its most advanced product candidate, EPZ-5676, an inhibitor targeting the DOT1L HMT, for the treatment of mixed lineage rearranged leukemia.

HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression.

In the second quarter of 2013, the company expects to begin a Phase 1/2 clinical trial of its second most advanced product candidate, EPZ-6438, an inhibitor targeting the EZH2 HMT, for the treatment of a genetically defined subtype of non-Hodgkin lymphoma.

[Related -Is The Slump In US Manufacturing Easing?]

The company expects to use the net proceeds from the offering to fund the costs of Phase 1 clinical development of EPZ-5676, to fund research and development and advance its pipeline of preclinical product candidates and for working capital and general corporate purposes.

For the year ended December 2012, loss attributable to common stockholders was $1.19 million on collaboration revenue of $45.22 million.

The company, which was founded in November 2007, has applied to list its common stock on the NASDAQ under the symbol "EPZM."

Citigroup (C), Cowen and Co. and Leerink Swann are the joint bookrunners on the offering.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageEmerging-Markets Stocks Took The Lead Last Week

Emerging-markets equities enjoyed a solid rise last week among the major asset classes, based on a set of read on...

article imageDoes Your Latest Investment Pass This Test?

On Wednesday, I sounded the alarm about the problems looming for some consumer staples stocks. In short, read on...

article imageIs The Slump In US Manufacturing Easing?

Yesterday’s November survey data from the Philadelphia Fed hints at the possibility that a stronger trend read on...

article imageMarket Potentially Facing Near Term Technical Headwinds

After the S&P 500 Index pullback on Thursday and Friday last week, the market's advance on Monday and read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.